Security Notice: Please be aware of impersonation attempts using our company name
Legitimate communications from Ascent Research will only come from official @ascentresearch.com email addresses.
Quick Order Cart

Cat. No. ARG40875

EHMT2 Knockout KYSE150 Polyclonal Cells

  • Product Type:

    Polyclonal Cell Population

  • Species:

    Homo sapiens (Human)

  • Tissue Source:

    Esophagus

  • Disease:

    Squamous cell carcinoma

EHMT2 Knockout KYSE-150 Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout population with disruption of the EHMT2 gene in the human esophageal squamous cell carcinoma cell line KYSE-150. EHMT2 encodes a histone methyltransferase that deposits H3K9me2/me3, leading to transcriptional repression of tumor suppressors such as CDKN1A. This loss-of-function model is suitable for investigating epigenetic mechanisms in ESCC, including changes in H3K9 methylation and gene reactivation. Applications span western blot, ChIP-qPCR, RT-qPCR, proliferation and apoptosis assays, and drug sensitivity testing with EHMT2 inhibitors.

Inquire Now

In stock

Ships next business day


Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice


Disclaimer:

For Research Use Only

  • Characteristics

    Host Cell

    KYSE-150

    Sex of Donor

    Female

    Age

    49 years

    Gene Name

    EHMT2

    Gene Identifier

    NCBI Gene ID 10919

    Morphology

    Epithelial-like

    Growth Mode

    Adherent

    Storage

    Liquid nitrogen (LN2)

  • Culture Conditions

    Growth medium

    RPMI 1640:Ham's F-12(1:1)

    Supplement(s)

    10% Fetal Bovine Serum, 1% Penicillin-Streptomycin Solution

    Temperature

    37°C

    Atmosphere

    5% CO₂

  • Quality Control

    Sterility testing

    The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

    Mycoplasma testing

    Negative for mycoplasma through PCR analysis

  • Disclaimer

    Intended Use

    This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.

    Disclaimer

    Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

    By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

    This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

The EHMT2 Knockout KYSE-150 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population with targeted disruption of the EHMT2 gene, providing a loss-of-function model for epigenetic studies in esophageal squamous cell carcinoma. This polyclonal format eliminates the need for single-cell cloning and captures a spectrum of genetic edits, enabling robust functional analyses.

The KYSE-150 cell line, derived from a human esophageal squamous cell carcinoma, is a widely used model for investigating ESCC biology. These adherent epithelial cells exhibit characteristics of squamous cell carcinoma, making them suitable for dissecting oncogenic signaling, proliferation, and therapeutic vulnerabilities.

EHMT2 (G9a) is a histone-lysine N-methyltransferase that methylates histone H3 at lysine 9 to generate H3K9me1/me2/me3, marks recognized by HP1 and associated with transcriptional repression. It functions in complexes with EHMT1, DNMTs, MBD2, and PRC2 components, integrating DNA and histone methylation. Upstream regulators include MYC, E2F1, and PI3K/AKT pathways. EHMT2 deposits H3K9me2 at promoters of tumor suppressors like CDKN1A and CDH1, silencing their expression and promoting proliferation. It also contributes to WNT signaling, DNA repair, and cellular senescence.

In ESCC, EHMT2 is often overexpressed, driving tumor progression through epigenetic silencing. The KYSE-150 background provides a disease-relevant context in which knockout of EHMT2 can reactivate tumor suppressor programs, revealing mechanisms of epigenetic dysregulation. This model is valuable for examining the role of EHMT2 in proliferation, apoptosis, and drug response.

Applications include western blot for H3K9me2/me3, ChIP-qPCR at specific loci, RT-qPCR for CDKN1A and CDH1, RNA-seq, and functional assays such as proliferation, colony formation, and apoptosis. These cells are also useful for testing EHMT2 inhibitors like UNC0642 and BIX-01294, and for target validation studies in cancer epigenetics. For more information, contact Ascent Research.

Reset Password

    Reach Us Questions? Click Me Here!

    Fill out the form below and a member of our team will contact you shortly!

    *Required field



      Reach Us

      Fill out the form below and a member of our team will contact you shortly!

      *Required field

      Product Inquiry (Optional)